All lobbying filings

Biogen

Biogen filed a Q3 report for Biogen on October 20, 2025.

Lobbying for Biogen

As filed: BIOGEN for BIOGEN.

All filings by Biogen · Everything Biogen has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 20, 2025

Expenses

$990,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 5

Pharmacy

Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies. Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill.

Taxation/Internal Revenue Code

Issues related to tax reform and tax policy, implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97), policies related to OECD on the taxation of global income.

Health Issues

Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials

Medicare/Medicaid

Discussions regarding drug cost and pricing policy and issues related to the Medicaid 340B progran, no specific bill.

Trade (domestic/foreign)

Trade-related public policy around tariffs and intellectual property, no related bills

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.